Global Therapeutic Radioligands Supply, Demand and Key Producers, 2023-2029
The global Therapeutic Radioligands market size is expected to reach $ 3154.4 million by 2029, rising at a market growth of 16.7% CAGR during the forecast period (2023-2029).
The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.
Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report studies the global Therapeutic Radioligands demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Therapeutic Radioligands, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Therapeutic Radioligands that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Therapeutic Radioligands total market, 2018-2029, (USD Million)
Global Therapeutic Radioligands total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Therapeutic Radioligands total market, key domestic companies and share, (USD Million)
Global Therapeutic Radioligands revenue by player and market share 2018-2023, (USD Million)
Global Therapeutic Radioligands total market by Type, CAGR, 2018-2029, (USD Million)
Global Therapeutic Radioligands total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Therapeutic Radioligands market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Therapeutic Radioligands market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Therapeutic Radioligands Market, By Region:
1. How big is the global Therapeutic Radioligands market?
2. What is the demand of the global Therapeutic Radioligands market?
3. What is the year over year growth of the global Therapeutic Radioligands market?
4. What is the total value of the global Therapeutic Radioligands market?
5. Who are the major players in the global Therapeutic Radioligands market?
The key drivers of the radioimmunotherapy market is its potential to deliver highly targeted and precise treatment to cancer cells, sparing healthy tissues and reducing side effects compared to traditional radiation therapies. The ability of RIT to offer personalized treatment options based on specific cancer biomarkers further enhances its appeal in the field of precision medicine. However, the radioimmunotherapy market also faces challenges. One major challenge is the high cost associated with the development and production of radiopharmaceuticals, limiting access for some patients and healthcare systems. Additionally, navigating complex regulatory pathways for approval and reimbursement of RIT products can be time-consuming and resource-intensive for pharmaceutical companies. Furthermore, there may be limited awareness and acceptance of RIT among healthcare professionals and patients, leading to slower adoption rates and market penetration. Addressing these challenges requires continued research and investment in RIT technologies to improve efficacy and cost-effectiveness. Collaborations between pharmaceutical companies, research institutions, and healthcare organizations can facilitate knowledge-sharing and streamline the regulatory process.
Therapeutic Radioligands is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
This report studies the global Therapeutic Radioligands demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Therapeutic Radioligands, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Therapeutic Radioligands that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Therapeutic Radioligands total market, 2018-2029, (USD Million)
Global Therapeutic Radioligands total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Therapeutic Radioligands total market, key domestic companies and share, (USD Million)
Global Therapeutic Radioligands revenue by player and market share 2018-2023, (USD Million)
Global Therapeutic Radioligands total market by Type, CAGR, 2018-2029, (USD Million)
Global Therapeutic Radioligands total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Therapeutic Radioligands market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bayer, Novartis, Lantheus, Aurobindo Pharma, Mundipharma, China Isotope & Radiation, Curium Pharmaceuticals, Gilead Sciences and Clarity Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Therapeutic Radioligands market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Therapeutic Radioligands Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Beta-emitting
- Targeted Alpha Therapy
- Solid Tumor
- Non Hodgkin Lymphoma
- Bayer
- Novartis
- Lantheus
- Aurobindo Pharma
- Mundipharma
- China Isotope & Radiation
- Curium Pharmaceuticals
- Gilead Sciences
- Clarity Pharmaceuticals
- Curasight
- Nordic Nanovector
- Philogen
- RadioMedix
- Telix Pharmaceuticals
- Orano Med
- Actinium Pharmaceuticals
- Y-mAbs Therapeutics
- Fusion Pharmaceuticals
1. How big is the global Therapeutic Radioligands market?
2. What is the demand of the global Therapeutic Radioligands market?
3. What is the year over year growth of the global Therapeutic Radioligands market?
4. What is the total value of the global Therapeutic Radioligands market?
5. Who are the major players in the global Therapeutic Radioligands market?
1 SUPPLY SUMMARY
1.1 Therapeutic Radioligands Introduction
1.2 World Therapeutic Radioligands Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Therapeutic Radioligands Total Market by Region (by Headquarter Location)
1.3.1 World Therapeutic Radioligands Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Therapeutic Radioligands Market Size (2018-2029)
1.3.3 China Therapeutic Radioligands Market Size (2018-2029)
1.3.4 Europe Therapeutic Radioligands Market Size (2018-2029)
1.3.5 Japan Therapeutic Radioligands Market Size (2018-2029)
1.3.6 South Korea Therapeutic Radioligands Market Size (2018-2029)
1.3.7 ASEAN Therapeutic Radioligands Market Size (2018-2029)
1.3.8 India Therapeutic Radioligands Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Therapeutic Radioligands Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Therapeutic Radioligands Major Market Trends
2 DEMAND SUMMARY
2.1 World Therapeutic Radioligands Consumption Value (2018-2029)
2.2 World Therapeutic Radioligands Consumption Value by Region
2.2.1 World Therapeutic Radioligands Consumption Value by Region (2018-2023)
2.2.2 World Therapeutic Radioligands Consumption Value Forecast by Region (2024-2029)
2.3 United States Therapeutic Radioligands Consumption Value (2018-2029)
2.4 China Therapeutic Radioligands Consumption Value (2018-2029)
2.5 Europe Therapeutic Radioligands Consumption Value (2018-2029)
2.6 Japan Therapeutic Radioligands Consumption Value (2018-2029)
2.7 South Korea Therapeutic Radioligands Consumption Value (2018-2029)
2.8 ASEAN Therapeutic Radioligands Consumption Value (2018-2029)
2.9 India Therapeutic Radioligands Consumption Value (2018-2029)
3 WORLD THERAPEUTIC RADIOLIGANDS COMPANIES COMPETITIVE ANALYSIS
3.1 World Therapeutic Radioligands Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Therapeutic Radioligands Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Therapeutic Radioligands in 2022
3.2.3 Global Concentration Ratios (CR8) for Therapeutic Radioligands in 2022
3.3 Therapeutic Radioligands Company Evaluation Quadrant
3.4 Therapeutic Radioligands Market: Overall Company Footprint Analysis
3.4.1 Therapeutic Radioligands Market: Region Footprint
3.4.2 Therapeutic Radioligands Market: Company Product Type Footprint
3.4.3 Therapeutic Radioligands Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Therapeutic Radioligands Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Therapeutic Radioligands Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Therapeutic Radioligands Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Therapeutic Radioligands Consumption Value Comparison
4.2.1 United States VS China: Therapeutic Radioligands Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Therapeutic Radioligands Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Therapeutic Radioligands Companies and Market Share, 2018-2023
4.3.1 United States Based Therapeutic Radioligands Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Therapeutic Radioligands Revenue, (2018-2023)
4.4 China Based Companies Therapeutic Radioligands Revenue and Market Share, 2018-2023
4.4.1 China Based Therapeutic Radioligands Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Therapeutic Radioligands Revenue, (2018-2023)
4.5 Rest of World Based Therapeutic Radioligands Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Therapeutic Radioligands Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Therapeutic Radioligands Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Therapeutic Radioligands Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Beta-emitting
5.2.2 Targeted Alpha Therapy
5.3 Market Segment by Type
5.3.1 World Therapeutic Radioligands Market Size by Type (2018-2023)
5.3.2 World Therapeutic Radioligands Market Size by Type (2024-2029)
5.3.3 World Therapeutic Radioligands Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Therapeutic Radioligands Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Solid Tumor
6.2.2 Non Hodgkin Lymphoma
6.3 Market Segment by Application
6.3.1 World Therapeutic Radioligands Market Size by Application (2018-2023)
6.3.2 World Therapeutic Radioligands Market Size by Application (2024-2029)
6.3.3 World Therapeutic Radioligands Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Therapeutic Radioligands Product and Services
7.1.4 Bayer Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Therapeutic Radioligands Product and Services
7.2.4 Novartis Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Lantheus
7.3.1 Lantheus Details
7.3.2 Lantheus Major Business
7.3.3 Lantheus Therapeutic Radioligands Product and Services
7.3.4 Lantheus Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Lantheus Recent Developments/Updates
7.3.6 Lantheus Competitive Strengths & Weaknesses
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Details
7.4.2 Aurobindo Pharma Major Business
7.4.3 Aurobindo Pharma Therapeutic Radioligands Product and Services
7.4.4 Aurobindo Pharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Aurobindo Pharma Recent Developments/Updates
7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.5 Mundipharma
7.5.1 Mundipharma Details
7.5.2 Mundipharma Major Business
7.5.3 Mundipharma Therapeutic Radioligands Product and Services
7.5.4 Mundipharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Mundipharma Recent Developments/Updates
7.5.6 Mundipharma Competitive Strengths & Weaknesses
7.6 China Isotope & Radiation
7.6.1 China Isotope & Radiation Details
7.6.2 China Isotope & Radiation Major Business
7.6.3 China Isotope & Radiation Therapeutic Radioligands Product and Services
7.6.4 China Isotope & Radiation Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 China Isotope & Radiation Recent Developments/Updates
7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
7.7 Curium Pharmaceuticals
7.7.1 Curium Pharmaceuticals Details
7.7.2 Curium Pharmaceuticals Major Business
7.7.3 Curium Pharmaceuticals Therapeutic Radioligands Product and Services
7.7.4 Curium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharmaceuticals Recent Developments/Updates
7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Therapeutic Radioligands Product and Services
7.8.4 Gilead Sciences Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 Clarity Pharmaceuticals
7.9.1 Clarity Pharmaceuticals Details
7.9.2 Clarity Pharmaceuticals Major Business
7.9.3 Clarity Pharmaceuticals Therapeutic Radioligands Product and Services
7.9.4 Clarity Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
7.10 Curasight
7.10.1 Curasight Details
7.10.2 Curasight Major Business
7.10.3 Curasight Therapeutic Radioligands Product and Services
7.10.4 Curasight Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Curasight Recent Developments/Updates
7.10.6 Curasight Competitive Strengths & Weaknesses
7.11 Nordic Nanovector
7.11.1 Nordic Nanovector Details
7.11.2 Nordic Nanovector Major Business
7.11.3 Nordic Nanovector Therapeutic Radioligands Product and Services
7.11.4 Nordic Nanovector Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Nordic Nanovector Recent Developments/Updates
7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses
7.12 Philogen
7.12.1 Philogen Details
7.12.2 Philogen Major Business
7.12.3 Philogen Therapeutic Radioligands Product and Services
7.12.4 Philogen Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Philogen Recent Developments/Updates
7.12.6 Philogen Competitive Strengths & Weaknesses
7.13 RadioMedix
7.13.1 RadioMedix Details
7.13.2 RadioMedix Major Business
7.13.3 RadioMedix Therapeutic Radioligands Product and Services
7.13.4 RadioMedix Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 RadioMedix Recent Developments/Updates
7.13.6 RadioMedix Competitive Strengths & Weaknesses
7.14 Telix Pharmaceuticals
7.14.1 Telix Pharmaceuticals Details
7.14.2 Telix Pharmaceuticals Major Business
7.14.3 Telix Pharmaceuticals Therapeutic Radioligands Product and Services
7.14.4 Telix Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Telix Pharmaceuticals Recent Developments/Updates
7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
7.15 Orano Med
7.15.1 Orano Med Details
7.15.2 Orano Med Major Business
7.15.3 Orano Med Therapeutic Radioligands Product and Services
7.15.4 Orano Med Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Orano Med Recent Developments/Updates
7.15.6 Orano Med Competitive Strengths & Weaknesses
7.16 Actinium Pharmaceuticals
7.16.1 Actinium Pharmaceuticals Details
7.16.2 Actinium Pharmaceuticals Major Business
7.16.3 Actinium Pharmaceuticals Therapeutic Radioligands Product and Services
7.16.4 Actinium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
7.17 Y-mAbs Therapeutics
7.17.1 Y-mAbs Therapeutics Details
7.17.2 Y-mAbs Therapeutics Major Business
7.17.3 Y-mAbs Therapeutics Therapeutic Radioligands Product and Services
7.17.4 Y-mAbs Therapeutics Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.18 Fusion Pharmaceuticals
7.18.1 Fusion Pharmaceuticals Details
7.18.2 Fusion Pharmaceuticals Major Business
7.18.3 Fusion Pharmaceuticals Therapeutic Radioligands Product and Services
7.18.4 Fusion Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Therapeutic Radioligands Industry Chain
8.2 Therapeutic Radioligands Upstream Analysis
8.3 Therapeutic Radioligands Midstream Analysis
8.4 Therapeutic Radioligands Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Therapeutic Radioligands Introduction
1.2 World Therapeutic Radioligands Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Therapeutic Radioligands Total Market by Region (by Headquarter Location)
1.3.1 World Therapeutic Radioligands Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Therapeutic Radioligands Market Size (2018-2029)
1.3.3 China Therapeutic Radioligands Market Size (2018-2029)
1.3.4 Europe Therapeutic Radioligands Market Size (2018-2029)
1.3.5 Japan Therapeutic Radioligands Market Size (2018-2029)
1.3.6 South Korea Therapeutic Radioligands Market Size (2018-2029)
1.3.7 ASEAN Therapeutic Radioligands Market Size (2018-2029)
1.3.8 India Therapeutic Radioligands Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Therapeutic Radioligands Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Therapeutic Radioligands Major Market Trends
2 DEMAND SUMMARY
2.1 World Therapeutic Radioligands Consumption Value (2018-2029)
2.2 World Therapeutic Radioligands Consumption Value by Region
2.2.1 World Therapeutic Radioligands Consumption Value by Region (2018-2023)
2.2.2 World Therapeutic Radioligands Consumption Value Forecast by Region (2024-2029)
2.3 United States Therapeutic Radioligands Consumption Value (2018-2029)
2.4 China Therapeutic Radioligands Consumption Value (2018-2029)
2.5 Europe Therapeutic Radioligands Consumption Value (2018-2029)
2.6 Japan Therapeutic Radioligands Consumption Value (2018-2029)
2.7 South Korea Therapeutic Radioligands Consumption Value (2018-2029)
2.8 ASEAN Therapeutic Radioligands Consumption Value (2018-2029)
2.9 India Therapeutic Radioligands Consumption Value (2018-2029)
3 WORLD THERAPEUTIC RADIOLIGANDS COMPANIES COMPETITIVE ANALYSIS
3.1 World Therapeutic Radioligands Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Therapeutic Radioligands Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Therapeutic Radioligands in 2022
3.2.3 Global Concentration Ratios (CR8) for Therapeutic Radioligands in 2022
3.3 Therapeutic Radioligands Company Evaluation Quadrant
3.4 Therapeutic Radioligands Market: Overall Company Footprint Analysis
3.4.1 Therapeutic Radioligands Market: Region Footprint
3.4.2 Therapeutic Radioligands Market: Company Product Type Footprint
3.4.3 Therapeutic Radioligands Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Therapeutic Radioligands Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Therapeutic Radioligands Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Therapeutic Radioligands Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Therapeutic Radioligands Consumption Value Comparison
4.2.1 United States VS China: Therapeutic Radioligands Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Therapeutic Radioligands Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Therapeutic Radioligands Companies and Market Share, 2018-2023
4.3.1 United States Based Therapeutic Radioligands Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Therapeutic Radioligands Revenue, (2018-2023)
4.4 China Based Companies Therapeutic Radioligands Revenue and Market Share, 2018-2023
4.4.1 China Based Therapeutic Radioligands Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Therapeutic Radioligands Revenue, (2018-2023)
4.5 Rest of World Based Therapeutic Radioligands Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Therapeutic Radioligands Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Therapeutic Radioligands Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Therapeutic Radioligands Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Beta-emitting
5.2.2 Targeted Alpha Therapy
5.3 Market Segment by Type
5.3.1 World Therapeutic Radioligands Market Size by Type (2018-2023)
5.3.2 World Therapeutic Radioligands Market Size by Type (2024-2029)
5.3.3 World Therapeutic Radioligands Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Therapeutic Radioligands Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Solid Tumor
6.2.2 Non Hodgkin Lymphoma
6.3 Market Segment by Application
6.3.1 World Therapeutic Radioligands Market Size by Application (2018-2023)
6.3.2 World Therapeutic Radioligands Market Size by Application (2024-2029)
6.3.3 World Therapeutic Radioligands Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 Bayer
7.1.1 Bayer Details
7.1.2 Bayer Major Business
7.1.3 Bayer Therapeutic Radioligands Product and Services
7.1.4 Bayer Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 Bayer Recent Developments/Updates
7.1.6 Bayer Competitive Strengths & Weaknesses
7.2 Novartis
7.2.1 Novartis Details
7.2.2 Novartis Major Business
7.2.3 Novartis Therapeutic Radioligands Product and Services
7.2.4 Novartis Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Novartis Recent Developments/Updates
7.2.6 Novartis Competitive Strengths & Weaknesses
7.3 Lantheus
7.3.1 Lantheus Details
7.3.2 Lantheus Major Business
7.3.3 Lantheus Therapeutic Radioligands Product and Services
7.3.4 Lantheus Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Lantheus Recent Developments/Updates
7.3.6 Lantheus Competitive Strengths & Weaknesses
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Details
7.4.2 Aurobindo Pharma Major Business
7.4.3 Aurobindo Pharma Therapeutic Radioligands Product and Services
7.4.4 Aurobindo Pharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Aurobindo Pharma Recent Developments/Updates
7.4.6 Aurobindo Pharma Competitive Strengths & Weaknesses
7.5 Mundipharma
7.5.1 Mundipharma Details
7.5.2 Mundipharma Major Business
7.5.3 Mundipharma Therapeutic Radioligands Product and Services
7.5.4 Mundipharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Mundipharma Recent Developments/Updates
7.5.6 Mundipharma Competitive Strengths & Weaknesses
7.6 China Isotope & Radiation
7.6.1 China Isotope & Radiation Details
7.6.2 China Isotope & Radiation Major Business
7.6.3 China Isotope & Radiation Therapeutic Radioligands Product and Services
7.6.4 China Isotope & Radiation Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 China Isotope & Radiation Recent Developments/Updates
7.6.6 China Isotope & Radiation Competitive Strengths & Weaknesses
7.7 Curium Pharmaceuticals
7.7.1 Curium Pharmaceuticals Details
7.7.2 Curium Pharmaceuticals Major Business
7.7.3 Curium Pharmaceuticals Therapeutic Radioligands Product and Services
7.7.4 Curium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Curium Pharmaceuticals Recent Developments/Updates
7.7.6 Curium Pharmaceuticals Competitive Strengths & Weaknesses
7.8 Gilead Sciences
7.8.1 Gilead Sciences Details
7.8.2 Gilead Sciences Major Business
7.8.3 Gilead Sciences Therapeutic Radioligands Product and Services
7.8.4 Gilead Sciences Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Gilead Sciences Recent Developments/Updates
7.8.6 Gilead Sciences Competitive Strengths & Weaknesses
7.9 Clarity Pharmaceuticals
7.9.1 Clarity Pharmaceuticals Details
7.9.2 Clarity Pharmaceuticals Major Business
7.9.3 Clarity Pharmaceuticals Therapeutic Radioligands Product and Services
7.9.4 Clarity Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Clarity Pharmaceuticals Recent Developments/Updates
7.9.6 Clarity Pharmaceuticals Competitive Strengths & Weaknesses
7.10 Curasight
7.10.1 Curasight Details
7.10.2 Curasight Major Business
7.10.3 Curasight Therapeutic Radioligands Product and Services
7.10.4 Curasight Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Curasight Recent Developments/Updates
7.10.6 Curasight Competitive Strengths & Weaknesses
7.11 Nordic Nanovector
7.11.1 Nordic Nanovector Details
7.11.2 Nordic Nanovector Major Business
7.11.3 Nordic Nanovector Therapeutic Radioligands Product and Services
7.11.4 Nordic Nanovector Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Nordic Nanovector Recent Developments/Updates
7.11.6 Nordic Nanovector Competitive Strengths & Weaknesses
7.12 Philogen
7.12.1 Philogen Details
7.12.2 Philogen Major Business
7.12.3 Philogen Therapeutic Radioligands Product and Services
7.12.4 Philogen Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Philogen Recent Developments/Updates
7.12.6 Philogen Competitive Strengths & Weaknesses
7.13 RadioMedix
7.13.1 RadioMedix Details
7.13.2 RadioMedix Major Business
7.13.3 RadioMedix Therapeutic Radioligands Product and Services
7.13.4 RadioMedix Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 RadioMedix Recent Developments/Updates
7.13.6 RadioMedix Competitive Strengths & Weaknesses
7.14 Telix Pharmaceuticals
7.14.1 Telix Pharmaceuticals Details
7.14.2 Telix Pharmaceuticals Major Business
7.14.3 Telix Pharmaceuticals Therapeutic Radioligands Product and Services
7.14.4 Telix Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Telix Pharmaceuticals Recent Developments/Updates
7.14.6 Telix Pharmaceuticals Competitive Strengths & Weaknesses
7.15 Orano Med
7.15.1 Orano Med Details
7.15.2 Orano Med Major Business
7.15.3 Orano Med Therapeutic Radioligands Product and Services
7.15.4 Orano Med Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Orano Med Recent Developments/Updates
7.15.6 Orano Med Competitive Strengths & Weaknesses
7.16 Actinium Pharmaceuticals
7.16.1 Actinium Pharmaceuticals Details
7.16.2 Actinium Pharmaceuticals Major Business
7.16.3 Actinium Pharmaceuticals Therapeutic Radioligands Product and Services
7.16.4 Actinium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Actinium Pharmaceuticals Recent Developments/Updates
7.16.6 Actinium Pharmaceuticals Competitive Strengths & Weaknesses
7.17 Y-mAbs Therapeutics
7.17.1 Y-mAbs Therapeutics Details
7.17.2 Y-mAbs Therapeutics Major Business
7.17.3 Y-mAbs Therapeutics Therapeutic Radioligands Product and Services
7.17.4 Y-mAbs Therapeutics Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Y-mAbs Therapeutics Recent Developments/Updates
7.17.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.18 Fusion Pharmaceuticals
7.18.1 Fusion Pharmaceuticals Details
7.18.2 Fusion Pharmaceuticals Major Business
7.18.3 Fusion Pharmaceuticals Therapeutic Radioligands Product and Services
7.18.4 Fusion Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Fusion Pharmaceuticals Recent Developments/Updates
7.18.6 Fusion Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Therapeutic Radioligands Industry Chain
8.2 Therapeutic Radioligands Upstream Analysis
8.3 Therapeutic Radioligands Midstream Analysis
8.4 Therapeutic Radioligands Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Therapeutic Radioligands Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Therapeutic Radioligands Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Therapeutic Radioligands Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Therapeutic Radioligands Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Therapeutic Radioligands Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Therapeutic Radioligands Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Therapeutic Radioligands Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Therapeutic Radioligands Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Therapeutic Radioligands Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Therapeutic Radioligands Players in 2022
Table 12. World Therapeutic Radioligands Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Therapeutic Radioligands Company Evaluation Quadrant
Table 14. Head Office of Key Therapeutic Radioligands Player
Table 15. Therapeutic Radioligands Market: Company Product Type Footprint
Table 16. Therapeutic Radioligands Market: Company Product Application Footprint
Table 17. Therapeutic Radioligands Mergers & Acquisitions Activity
Table 18. United States VS China Therapeutic Radioligands Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Therapeutic Radioligands Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Therapeutic Radioligands Companies, Headquarters (States, Country)
Table 21. United States Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
Table 23. China Based Therapeutic Radioligands Companies, Headquarters (Province, Country)
Table 24. China Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
Table 26. Rest of World Based Therapeutic Radioligands Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
Table 29. World Therapeutic Radioligands Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Therapeutic Radioligands Market Size by Type (2018-2023) & (USD Million)
Table 31. World Therapeutic Radioligands Market Size by Type (2024-2029) & (USD Million)
Table 32. World Therapeutic Radioligands Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Therapeutic Radioligands Market Size by Application (2018-2023) & (USD Million)
Table 34. World Therapeutic Radioligands Market Size by Application (2024-2029) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Therapeutic Radioligands Product and Services
Table 38. Bayer Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Therapeutic Radioligands Product and Services
Table 44. Novartis Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Lantheus Basic Information, Area Served and Competitors
Table 48. Lantheus Major Business
Table 49. Lantheus Therapeutic Radioligands Product and Services
Table 50. Lantheus Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Lantheus Recent Developments/Updates
Table 52. Lantheus Competitive Strengths & Weaknesses
Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 54. Aurobindo Pharma Major Business
Table 55. Aurobindo Pharma Therapeutic Radioligands Product and Services
Table 56. Aurobindo Pharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Aurobindo Pharma Recent Developments/Updates
Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 59. Mundipharma Basic Information, Area Served and Competitors
Table 60. Mundipharma Major Business
Table 61. Mundipharma Therapeutic Radioligands Product and Services
Table 62. Mundipharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Mundipharma Recent Developments/Updates
Table 64. Mundipharma Competitive Strengths & Weaknesses
Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors
Table 66. China Isotope & Radiation Major Business
Table 67. China Isotope & Radiation Therapeutic Radioligands Product and Services
Table 68. China Isotope & Radiation Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. China Isotope & Radiation Recent Developments/Updates
Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Curium Pharmaceuticals Major Business
Table 73. Curium Pharmaceuticals Therapeutic Radioligands Product and Services
Table 74. Curium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharmaceuticals Recent Developments/Updates
Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Therapeutic Radioligands Product and Services
Table 80. Gilead Sciences Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
Table 84. Clarity Pharmaceuticals Major Business
Table 85. Clarity Pharmaceuticals Therapeutic Radioligands Product and Services
Table 86. Clarity Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Clarity Pharmaceuticals Recent Developments/Updates
Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
Table 89. Curasight Basic Information, Area Served and Competitors
Table 90. Curasight Major Business
Table 91. Curasight Therapeutic Radioligands Product and Services
Table 92. Curasight Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Curasight Recent Developments/Updates
Table 94. Curasight Competitive Strengths & Weaknesses
Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
Table 96. Nordic Nanovector Major Business
Table 97. Nordic Nanovector Therapeutic Radioligands Product and Services
Table 98. Nordic Nanovector Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Nordic Nanovector Recent Developments/Updates
Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
Table 101. Philogen Basic Information, Area Served and Competitors
Table 102. Philogen Major Business
Table 103. Philogen Therapeutic Radioligands Product and Services
Table 104. Philogen Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Philogen Recent Developments/Updates
Table 106. Philogen Competitive Strengths & Weaknesses
Table 107. RadioMedix Basic Information, Area Served and Competitors
Table 108. RadioMedix Major Business
Table 109. RadioMedix Therapeutic Radioligands Product and Services
Table 110. RadioMedix Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. RadioMedix Recent Developments/Updates
Table 112. RadioMedix Competitive Strengths & Weaknesses
Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
Table 114. Telix Pharmaceuticals Major Business
Table 115. Telix Pharmaceuticals Therapeutic Radioligands Product and Services
Table 116. Telix Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Telix Pharmaceuticals Recent Developments/Updates
Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 119. Orano Med Basic Information, Area Served and Competitors
Table 120. Orano Med Major Business
Table 121. Orano Med Therapeutic Radioligands Product and Services
Table 122. Orano Med Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Orano Med Recent Developments/Updates
Table 124. Orano Med Competitive Strengths & Weaknesses
Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
Table 126. Actinium Pharmaceuticals Major Business
Table 127. Actinium Pharmaceuticals Therapeutic Radioligands Product and Services
Table 128. Actinium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Actinium Pharmaceuticals Recent Developments/Updates
Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 132. Y-mAbs Therapeutics Major Business
Table 133. Y-mAbs Therapeutics Therapeutic Radioligands Product and Services
Table 134. Y-mAbs Therapeutics Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Y-mAbs Therapeutics Recent Developments/Updates
Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
Table 137. Fusion Pharmaceuticals Major Business
Table 138. Fusion Pharmaceuticals Therapeutic Radioligands Product and Services
Table 139. Fusion Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Therapeutic Radioligands Upstream (Raw Materials)
Table 141. Therapeutic Radioligands Typical Customers
List of Figure
Figure 1. Therapeutic Radioligands Picture
Figure 2. World Therapeutic Radioligands Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Therapeutic Radioligands Total Market Size (2018-2029) & (USD Million)
Figure 4. World Therapeutic Radioligands Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Therapeutic Radioligands Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 13. Therapeutic Radioligands Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 16. World Therapeutic Radioligands Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 18. China Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 23. India Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Therapeutic Radioligands by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Therapeutic Radioligands Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Therapeutic Radioligands Markets in 2022
Figure 27. United States VS China: Therapeutic Radioligands Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Therapeutic Radioligands Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Therapeutic Radioligands Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Therapeutic Radioligands Market Size Market Share by Type in 2022
Figure 31. Beta-emitting
Figure 32. Targeted Alpha Therapy
Figure 33. World Therapeutic Radioligands Market Size Market Share by Type (2018-2029)
Figure 34. World Therapeutic Radioligands Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Therapeutic Radioligands Market Size Market Share by Application in 2022
Figure 36. Solid Tumor
Figure 37. Non Hodgkin Lymphoma
Figure 38. Therapeutic Radioligands Industrial Chain
Figure 39. Methodology
Figure 40. Research Process and Data Source
Table 1. World Therapeutic Radioligands Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Therapeutic Radioligands Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Therapeutic Radioligands Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Therapeutic Radioligands Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Therapeutic Radioligands Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Therapeutic Radioligands Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Therapeutic Radioligands Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Therapeutic Radioligands Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Therapeutic Radioligands Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Therapeutic Radioligands Players in 2022
Table 12. World Therapeutic Radioligands Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Therapeutic Radioligands Company Evaluation Quadrant
Table 14. Head Office of Key Therapeutic Radioligands Player
Table 15. Therapeutic Radioligands Market: Company Product Type Footprint
Table 16. Therapeutic Radioligands Market: Company Product Application Footprint
Table 17. Therapeutic Radioligands Mergers & Acquisitions Activity
Table 18. United States VS China Therapeutic Radioligands Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Therapeutic Radioligands Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Therapeutic Radioligands Companies, Headquarters (States, Country)
Table 21. United States Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
Table 23. China Based Therapeutic Radioligands Companies, Headquarters (Province, Country)
Table 24. China Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
Table 26. Rest of World Based Therapeutic Radioligands Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Therapeutic Radioligands Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Therapeutic Radioligands Revenue Market Share (2018-2023)
Table 29. World Therapeutic Radioligands Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Therapeutic Radioligands Market Size by Type (2018-2023) & (USD Million)
Table 31. World Therapeutic Radioligands Market Size by Type (2024-2029) & (USD Million)
Table 32. World Therapeutic Radioligands Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Therapeutic Radioligands Market Size by Application (2018-2023) & (USD Million)
Table 34. World Therapeutic Radioligands Market Size by Application (2024-2029) & (USD Million)
Table 35. Bayer Basic Information, Area Served and Competitors
Table 36. Bayer Major Business
Table 37. Bayer Therapeutic Radioligands Product and Services
Table 38. Bayer Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. Bayer Recent Developments/Updates
Table 40. Bayer Competitive Strengths & Weaknesses
Table 41. Novartis Basic Information, Area Served and Competitors
Table 42. Novartis Major Business
Table 43. Novartis Therapeutic Radioligands Product and Services
Table 44. Novartis Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Novartis Recent Developments/Updates
Table 46. Novartis Competitive Strengths & Weaknesses
Table 47. Lantheus Basic Information, Area Served and Competitors
Table 48. Lantheus Major Business
Table 49. Lantheus Therapeutic Radioligands Product and Services
Table 50. Lantheus Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Lantheus Recent Developments/Updates
Table 52. Lantheus Competitive Strengths & Weaknesses
Table 53. Aurobindo Pharma Basic Information, Area Served and Competitors
Table 54. Aurobindo Pharma Major Business
Table 55. Aurobindo Pharma Therapeutic Radioligands Product and Services
Table 56. Aurobindo Pharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Aurobindo Pharma Recent Developments/Updates
Table 58. Aurobindo Pharma Competitive Strengths & Weaknesses
Table 59. Mundipharma Basic Information, Area Served and Competitors
Table 60. Mundipharma Major Business
Table 61. Mundipharma Therapeutic Radioligands Product and Services
Table 62. Mundipharma Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Mundipharma Recent Developments/Updates
Table 64. Mundipharma Competitive Strengths & Weaknesses
Table 65. China Isotope & Radiation Basic Information, Area Served and Competitors
Table 66. China Isotope & Radiation Major Business
Table 67. China Isotope & Radiation Therapeutic Radioligands Product and Services
Table 68. China Isotope & Radiation Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. China Isotope & Radiation Recent Developments/Updates
Table 70. China Isotope & Radiation Competitive Strengths & Weaknesses
Table 71. Curium Pharmaceuticals Basic Information, Area Served and Competitors
Table 72. Curium Pharmaceuticals Major Business
Table 73. Curium Pharmaceuticals Therapeutic Radioligands Product and Services
Table 74. Curium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Curium Pharmaceuticals Recent Developments/Updates
Table 76. Curium Pharmaceuticals Competitive Strengths & Weaknesses
Table 77. Gilead Sciences Basic Information, Area Served and Competitors
Table 78. Gilead Sciences Major Business
Table 79. Gilead Sciences Therapeutic Radioligands Product and Services
Table 80. Gilead Sciences Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Gilead Sciences Recent Developments/Updates
Table 82. Gilead Sciences Competitive Strengths & Weaknesses
Table 83. Clarity Pharmaceuticals Basic Information, Area Served and Competitors
Table 84. Clarity Pharmaceuticals Major Business
Table 85. Clarity Pharmaceuticals Therapeutic Radioligands Product and Services
Table 86. Clarity Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Clarity Pharmaceuticals Recent Developments/Updates
Table 88. Clarity Pharmaceuticals Competitive Strengths & Weaknesses
Table 89. Curasight Basic Information, Area Served and Competitors
Table 90. Curasight Major Business
Table 91. Curasight Therapeutic Radioligands Product and Services
Table 92. Curasight Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Curasight Recent Developments/Updates
Table 94. Curasight Competitive Strengths & Weaknesses
Table 95. Nordic Nanovector Basic Information, Area Served and Competitors
Table 96. Nordic Nanovector Major Business
Table 97. Nordic Nanovector Therapeutic Radioligands Product and Services
Table 98. Nordic Nanovector Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Nordic Nanovector Recent Developments/Updates
Table 100. Nordic Nanovector Competitive Strengths & Weaknesses
Table 101. Philogen Basic Information, Area Served and Competitors
Table 102. Philogen Major Business
Table 103. Philogen Therapeutic Radioligands Product and Services
Table 104. Philogen Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Philogen Recent Developments/Updates
Table 106. Philogen Competitive Strengths & Weaknesses
Table 107. RadioMedix Basic Information, Area Served and Competitors
Table 108. RadioMedix Major Business
Table 109. RadioMedix Therapeutic Radioligands Product and Services
Table 110. RadioMedix Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. RadioMedix Recent Developments/Updates
Table 112. RadioMedix Competitive Strengths & Weaknesses
Table 113. Telix Pharmaceuticals Basic Information, Area Served and Competitors
Table 114. Telix Pharmaceuticals Major Business
Table 115. Telix Pharmaceuticals Therapeutic Radioligands Product and Services
Table 116. Telix Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Telix Pharmaceuticals Recent Developments/Updates
Table 118. Telix Pharmaceuticals Competitive Strengths & Weaknesses
Table 119. Orano Med Basic Information, Area Served and Competitors
Table 120. Orano Med Major Business
Table 121. Orano Med Therapeutic Radioligands Product and Services
Table 122. Orano Med Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Orano Med Recent Developments/Updates
Table 124. Orano Med Competitive Strengths & Weaknesses
Table 125. Actinium Pharmaceuticals Basic Information, Area Served and Competitors
Table 126. Actinium Pharmaceuticals Major Business
Table 127. Actinium Pharmaceuticals Therapeutic Radioligands Product and Services
Table 128. Actinium Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Actinium Pharmaceuticals Recent Developments/Updates
Table 130. Actinium Pharmaceuticals Competitive Strengths & Weaknesses
Table 131. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 132. Y-mAbs Therapeutics Major Business
Table 133. Y-mAbs Therapeutics Therapeutic Radioligands Product and Services
Table 134. Y-mAbs Therapeutics Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Y-mAbs Therapeutics Recent Developments/Updates
Table 136. Fusion Pharmaceuticals Basic Information, Area Served and Competitors
Table 137. Fusion Pharmaceuticals Major Business
Table 138. Fusion Pharmaceuticals Therapeutic Radioligands Product and Services
Table 139. Fusion Pharmaceuticals Therapeutic Radioligands Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Therapeutic Radioligands Upstream (Raw Materials)
Table 141. Therapeutic Radioligands Typical Customers
List of Figure
Figure 1. Therapeutic Radioligands Picture
Figure 2. World Therapeutic Radioligands Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Therapeutic Radioligands Total Market Size (2018-2029) & (USD Million)
Figure 4. World Therapeutic Radioligands Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Therapeutic Radioligands Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Therapeutic Radioligands Revenue (2018-2029) & (USD Million)
Figure 13. Therapeutic Radioligands Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 16. World Therapeutic Radioligands Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 18. China Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 23. India Therapeutic Radioligands Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Therapeutic Radioligands by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Therapeutic Radioligands Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Therapeutic Radioligands Markets in 2022
Figure 27. United States VS China: Therapeutic Radioligands Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Therapeutic Radioligands Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Therapeutic Radioligands Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Therapeutic Radioligands Market Size Market Share by Type in 2022
Figure 31. Beta-emitting
Figure 32. Targeted Alpha Therapy
Figure 33. World Therapeutic Radioligands Market Size Market Share by Type (2018-2029)
Figure 34. World Therapeutic Radioligands Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 35. World Therapeutic Radioligands Market Size Market Share by Application in 2022
Figure 36. Solid Tumor
Figure 37. Non Hodgkin Lymphoma
Figure 38. Therapeutic Radioligands Industrial Chain
Figure 39. Methodology
Figure 40. Research Process and Data Source
